2026-04-13T05:05:55Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/1301192025-12-05T09:23:17Zcom_2072_1057col_2072_478799col_2072_478858col_2072_478916col_2072_478908col_2072_478917
RECERCAT author Gómez Miragaya, Jorge author Palafox Sánchez, Marta author Paré, Laia author Yoldi, Guillermo author Ferrer, Irene author Vila, Sergi author Galván, Patricia author Pellegrini, Pasquale author Pérez-Montoyo, Hector author Igea, Ana author Muñoz Moruno, Purificación author Esteller, Manel author Nebreda, Àngel R. author Urruticoechea Ribate, Ander author Morilla, Idoia author Pernas, Sònia author Climent, Fina author Soler, María Teresa author Petit, Anna author Serra Elizalde, Violeta author Prat Aparicio, Aleix author González Suárez, Eva 2019-03-12T11:56:23Z2019-03-12T11:56:23Z2017-052019-03-12T11:56:23Z Taxanes are a mainstay of treatment for breast cancer, but resistance often develops followed by metastatic disease and mortality. Aiming to reveal the mechanisms underlying taxane resistance, we used breast cancer patient-derived orthoxenografts (PDX). Mimicking clinical behavior, triple-negative breast tumors (TNBCs) from PDX models were more sensitive to docetaxel than luminal tumors, but they progressively acquired resistance upon continuous drug administration. Mechanistically, we found that a CD49f+ chemoresistant population with tumor-initiating ability is present in sensitive tumors and expands during the acquisition of drug resistance. In the absence of the drug, the resistant CD49f+ population shrinks and taxane sensitivity is restored. We describe a transcriptional signature of resistance, predictive of recurrent disease after chemotherapy in TNBC. Together, these findings identify a CD49f+ population enriched in tumor-initiating ability and chemoresistance properties and evidence a drug holiday effect on the acquired resistance to docetaxel in triple-negative breast cancer. cc-by (c) Gómez Miragaya, Jorge et al., 2017 http://creativecommons.org/licenses/by/3.0/es info:eu-repo/semantics/openAccess Medicaments antineoplàstics Ús terapèutic Resistència als medicaments Metabolisme Integrines Càncer de mama Antineoplastic agents Therapeutic use Drug resistance Metabolism Integrins Breast cancer Resistance to taxanes in triple negative breast cancer associates with the dynamics of a CD49f+ tumor initiating population info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion